65,437 trials
Acute Decompensated Heart Failure
Primary: Percentage of Participants Experiencing Clinically Relevant Hypotension — 15.4; 16.7 Percent of participants
Gastric Cancer · Stomach Cancer · Esophageal Cancer
Primary: Number of Patients With Dose Limiting Toxicities — 0; 0 Participants
PreDiabetes
Primary: Change in Delay Discounting — -0.002; 0.108; -0.069; 0.035 time*indifference point/delay — p=0.0034
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the NRS — -1.98; -1.56 score on a scale
Metastatic Breast Cancer
Primary: Progression Free Survival (irPFS) — 21; 1; 3; 1 Participants
Acute Pain · Arthropathy of Knee · Arthropathy of Hip
Primary: Efficacy of NSS-2 Bridge Device in Changing Perioperative Opioid Consumption — 8.3; 33.5 mg morphine equivalent (MME)
Lung Cancer Stage III · Lung Cancer Stage IV
Primary: Number of Patients That Complete SST Treatment Sessions — 23 Participants
Schizophrenia · Schizoaffective Disorder
Primary: Neurocognitive Introspective Accuracy for Active vs. Sham Stimulation — .534; .526 score on a scale — p=.56
Metastatic Melanoma
Primary: Phase 2: Number of Participants With Objective Response Rate (ORR) Using RECIST v1.1 — 2; 9; 24; 14 Participants — p=0.0158
Triple Negative Breast Cancer
Primary: The Progression Free Survival (PFS) — 1.8 months
Urinary Incontinence
Primary: Acceptability of Test Hydrophilic Intermittent Catheter — 45; 4; 4; 2 Participants
Breast Cancer
Primary: 6-month Response Rate (Complete Response, Partial Response, and Stable Disease) — 9; 15; 4 Participants
Igel
Primary: Concentration of Propofol — 5.46; 3.82 ug/ml
Asthma
Primary: Lung Function, Specifically % Predicted Mean FEV1 — 92.9; 95.6; 88.6 percentage of predicted — p=>0.05
Human Immunodeficiency Virus (HIV) Positive
Primary: Number of Participants With Viral Load Suppression — 210; 213 Participants — p=0.220